Nav: Home

Study shows that Wnt secretion preventing drugs may reduce renal fibrosis

March 25, 2016

Renal fibrosis or the scarring of kidneys, following an injury, reduces their function and can cause kidney disease to progressively worsen. In a recent study, published in Kidney International, researchers from Duke-NUS Medical School (Duke-NUS) in Singapore and Duke University have shown that drugs that target Wnt secretion by inhibiting Porcupine, a protein usually targeted for cancer treatment, may reduce renal fibrosis and protect the kidneys.

In a patient with chronic kidney disease, the extent of their renal fibrosis usually predicts progression to end-stage kidney disease. Despite an intense focus of research in this area, no specific therapies are currently available to treat or reverse fibrosis in human chronic kidney disease. These diseases are debilitating and involve extremely high costs to the patients, who may need to undergo dialysis, and to the health care system, for recurring hospital admissions due to additional complications.

An effective drug would allow patients to lead more productive and independent lives. It would also have a positive impact on the healthcare system. As such, finding alternative treatments for renal fibrosis before it reaches this advanced stage, is necessary.

A team led by Assistant Professor Babita Madan and Professor David Virshup from Duke-NUS, and Associate Professor Steven D Crowley from Duke University, used a mouse model of kidney fibrosis to explore whether Wnt secretion inhibitors can be used to treat fibrosis. Wnt secretion inhibitors are presently being tested for the treatment of certain cancers.

In the study, one ureter, the tube from the kidney to the bladder, was blocked so that the affected kidney became damaged and scarred. The team demonstrated that inhibiting Wnt secretion interrupted the dangerous build-up of scar tissue in the kidney. These findings suggest a novel therapeutic approach to protect the kidney from scarring and provide a compelling rationale to test the use of Wnt secretion inhibitors for the treatment of kidney fibrosis and other progressive scarring disorders.

"This is the first study to demonstrate that a Wnt secretion inhibitor can be useful for preventing renal fibrosis," explained first author Dr Madan. "There could be potential long-term therapeutic treatments that could arise from this new knowledge, which can be explored for the treatment of additional fibrotic disorders including kidney disease."

Prof Virshup, Director of the Cancer and Stem Cell Biology Programme at Duke-NUS and Asst Prof Madan, in collaboration with A*STAR's Experimental Therapeutics Centre (ETC), have developed a novel Wnt secretion inhibitor, ETC-159. ETC-159 is presently in a Phase I clinical trial to target different cancers. Based on the findings of this study, it may be possible to test whether ETC-159 and other Wnt secretion inhibitors can be used to treat diseases other than cancer.
-end-
This research is supported by the Duke/Duke-NUS Research Collaboration Pilot Project Award.

Duke-NUS Medical School

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.